“JAK3 Inhibitor Shows Promise as Therapy for Steroid-Resistant Asthma by Suppressing Persistent and Active Steroid-Resistant Innate Lymphoid Cells (ILC2s)”

https://pubmed.ncbi.nlm.nih.gov/38117887

A JAK3 inhibitor shows promise as a therapy for steroid-resistant asthma by suppressing the persistence and activity of steroid-resistant innate lymphoid cells (ILC2s).